Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)

High Impact Clinical Trials ASN 2016 Howard Trachtman, Peter J. Nelson, Radko Komers In the phase 2 DUET trial that included 96 patients with focal segmental glomerulosclerosis (FSGS), sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, was evaluated to determine the impact on proteinuria. As compared to irbesartan, urinary protein excretion was suppressed to a greater extent than blockade of angiotensin II alone.  No hard clinical endpoints were evaluated. : Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Proteinuria: Is the ONTARGET renal substudy actually off target?
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Trial Results Conference Alert Source Type: research